๐ฐ Jonathan Silverberg News
Page 2 - Jonathan Silverberg News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Jonathan Silverberg. Real-time updates on events, politics, business and more.
February 28, 2024
Galderma the pureplay dermatology category leader will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology AAD Annual Meeting from March 812 2024 highlighting its broad innovative and leading dermatology portfolio.
January 4, 2024
Jonathan Silverberg, MD, PhD, MPH, of George Washington University School of Medicine and Health Sciences, explains the benefits of using Janus kinase (JAK) inhibitors to treat patients with atopic dermatitis (AD).
December 17, 2023
Our top coverage from this yearโs Revolutionizing Atopic Dermatitis (RAD) conference highlighted the evolving therapy landscape for patients with AD.
November 15, 2023
Studies show that early disease control lowers risk of developing other atopic morbidities
November 9, 2023
Operator: Good day and thank you for standing by. Welcome to the Nektar Therapeutics Third Quarter 2023 Financial Results Conference Call.
November 8, 2023
Dupilumab failure signals the need for extended patch testing to identify a missed diagnosis
November 3, 2023
Strong efficacy data for new class of agents in AD, but some apprehension over safety warnings
October 27, 2023
27.10.2023 - Positive topline data reported in July from TREK-AD, a Phase 2b study of eblasakimab in moderate-to-severe atopic dermatitis, met the primary endpoint across three dosing arms; the study established eblasakimabโs potential to deliver a monthly ...
October 24, 2023
(2023-10-24 | NDAQ:ASLN) ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
October 18, 2023
"This is the first study to demonstrate the therapeutic potential of rezpegaldesleukin," said Jonathan Silverberg, MD, PhD, MPH, who presented results of a phase 1b study.